Hero

Celyad Announces Third Quarter 2017 Business Update

1

Celyad Announces Third Quarter 2017 Business Update

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

2

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad announces new agreements with Celdara Medical and Dartmouth College

3

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

4

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

5

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad Announces Third Quarter 2017 Business Update

Celyad Announces Third Quarter 2017 Business Update

Conference call - Update on Clinical Strategy

Conference call - Update on Clinical Strategy

Discover all news

Carousel

Social Feed

RT @pharmabe: L’immunothérapie est une nouvelle piste prometteuse pour lutter contre le cancer. Les chercheurs tentent de mettre au point d…

2 weeks ago

RT @pharmabe: L’immunothérapie est une nouvelle piste prometteuse pour lutter contre le cancer. Les chercheurs tentent de mettre au point d…

@ChristianHomsy, CEO & David Gilham, VP R&D of Celyad will present a corporate update @PiperJaffrayCo 29th Healthca… https://t.co/HkkgkuDPf8

2 weeks ago

@ChristianHomsy, CEO & David Gilham, VP R&D of Celyad will present a corporate update @PiperJaffrayCo 29th Healthca… https://t.co/HkkgkuDPf8

Celyad Announces Third Quarter 2017 Business Update. Read the full press release https://t.co/fWGLGqUOeY https://t.co/YV1JnSBh5p

1 month ago

Celyad Announces Third Quarter 2017 Business Update. Read the full press release https://t.co/fWGLGqUOeY https://t.co/YV1JnSBh5p

Read the publication about Celyad's THINK study protocol in @bmj_company https://t.co/7igrpoOyVa https://t.co/bMrYB15WUQ

1 month ago

Read the publication about Celyad's THINK study protocol in @bmj_company https://t.co/7igrpoOyVa https://t.co/bMrYB15WUQ

RT @pharmabe: L’immunothérapie est une nouvelle piste prometteuse pour lutter contre le cancer. Les chercheurs tentent de mettre au point d…

2 weeks ago

RT @pharmabe: L’immunothérapie est une nouvelle piste prometteuse pour lutter contre le cancer. Les chercheurs tentent de mettre au point d…

@ChristianHomsy, CEO & David Gilham, VP R&D of Celyad will present a corporate update @PiperJaffrayCo 29th Healthca… https://t.co/HkkgkuDPf8

2 weeks ago

@ChristianHomsy, CEO & David Gilham, VP R&D of Celyad will present a corporate update @PiperJaffrayCo 29th Healthca… https://t.co/HkkgkuDPf8

Celyad Announces Third Quarter 2017 Business Update. Read the full press release https://t.co/fWGLGqUOeY https://t.co/YV1JnSBh5p

1 month ago

Celyad Announces Third Quarter 2017 Business Update. Read the full press release https://t.co/fWGLGqUOeY https://t.co/YV1JnSBh5p

Read the publication about Celyad's THINK study protocol in @bmj_company https://t.co/7igrpoOyVa https://t.co/bMrYB15WUQ

1 month ago

Read the publication about Celyad's THINK study protocol in @bmj_company https://t.co/7igrpoOyVa https://t.co/bMrYB15WUQ